Introduction
Chemotherapy resistance and relapse remain major challenges in the treatment of acute myeloid leukemia (AML), especially in the elderly. 1 The elucidation of the mechanisms underlying chemoresistance in AML may reveal novel targets for therapeutic intervention. Drug resistance in AML has been mainly attributed to P-glycoprotein (P-gP), an energy-depended pump which effluxes cytotoxic drugs out of the cell. 2 However, clinical attempts to target therapeutically the P-gP pump in AML have failed to show a clear benefit. 3, 4 Besides P-gP, additional cellular factors have been shown to contribute to drug resistance in AML, such as increased drug metabolism, 5 enhanced repair of chemotherapy-induced DNA damage 5 and increased survival due to overexpression of apoptosis inhibitors such as bcl-2. 6 c-Jun N-terminal kinase (JNK) is a protein kinase which is phosphorylated/activated after exposure of cells to stressful stimuli, such as irradiation and cancer chemotherapeutics. 7, 8 JNK belongs to the mitogen-activated protein (MAP) kinases superfamily, also including the extracellular signal-regulated kinase (ERK) and p38 family of kinases. 7 JNK activation has been shown to promote stress-induced apoptosis, however other reports suggest that JNK phosphorylation protects cells from apoptosis or plays no role in the process. 7, 9 Increased basal JNK activity has been associated with chemotherapy failure in AML by one study. 10 Similarly, elevated basal levels of phospho-ERK1/2 have been correlated with lower complete remission rates in adult ALL. 11 However, instead of examining steady-state expression levels of kinases in relation to therapeutic response, it has been suggested that the pharmacodynamic changes in the phosphorylation/activation status of signaling proteins should be preferentially evaluated. 12 For example, G-colony-stimulating factor-induced upregulation of phospho-STAT5 and STAT3 rather than their basal levels were associated with a poor response to induction chemotherapy in AML. 12 One study examining changes of JNK activity in an AML cell line showed a temporal association between anthracycline-induced apoptosis and JNK activation. 13, 14 However, it still remains unclear whether JNK activation is the critical step for anthracyclines to trigger apoptosis in AML. Indeed, studies in solid tumours have associated drug resistance with intrinsic failure of the cells to activate JNK. [15] [16] [17] [18] Whether chemoresistance in AML is attributed to JNK activation failure is not examined yet.
Here, we evaluated the activation of JNK in anthracyclinesensitive and resistant AML cell lines and in a series of primary AML bone marrow samples after exposure to anthracyclines. Furthermore, we silenced and activated the JNK pathway in transfected AML cell lines and evaluated its effect on anthracycline resistance. On the basis of our in vitro and in vivo results we show that a JNK-activation defect confers to chemoresistance in AML.
Materials and methods

Patient population and cell lines
A total of 29 AML patients diagnosed in our institution were enrolled in this study. Bone marrow aspirates were collected in sodium heparinate tubes at the initial diagnostic assessment and previously to treatment administration, after informed consent. Blast infiltration was evaluated morphologically and revealed a median infiltration of 60%. Samples underwent direct gradient centrifugation over Ficoll-Hypaque (Biochrom AG, Berlin, Germany). Patient clinical characteristics are detailed in Table 1 . Median patient age was 74 years and 26 out of the 29 patients studied were X55 years old. A total of 9 patients were offered palliative care whereas the remaining 20 patients received standard induction AML chemotherapy which included the anthracycline idarubicin (Table 1) . After first induction, 18 patients were alive and evaluated for response according to standard criteria. Complete response (CR) was defined as o5% blasts in bone marrow aspirate and normalization of peripheral blood cell counts whereas refractory disease was classified as persistent blasts in bone marrow or peripheral blood.
U937 acute myelomonocytic cell line was obtained from DSMZ (Braunschweig, Germany). U937R and URD40-resistant cells were derived from U937 cells exposed to nonlethal stepwise increasing concentrations of doxorubicin (DOX), as previously described. 19 
Cell culture and drug incubations
Primary leukemic cells and cell lines were maintained in standard medium containing RPMI 1640 (GIBCO; Invitrogen, Paisley, UK) supplemented with 10% fetal bovine serum (GIBCO), and antibiotics. 1 Â 10 6 per ml fresh AML marrow mononuclear cells or 0.2 Â 10 6 per ml exponentially growing U937 and U937R AML cells were cultured in six-well plates with or without 1 mM daunorubicin (DNR) or 1.5 mM DOX for various time points in standard medium at 37 1C in a humidified 95% O 2 and 5% CO 2 atmosphere. These anthracycline doses are reported to correspond to the peak plasma concentrations observed in AML patients undergoing induction therapy. 20 
Determination of phospho-JNK levels by western blot analysis
Following incubation with the drug, cell extracts were immediately prepared by resuspending the cell pellets on ice in radioimmuno-precipitation assay lysis buffer. The protein content of the extracts was determined using the BCA Protein Assay kit (Pierce Biotechnology, Rockford, IL, USA). A total of 50 mg cell protein was analyzed by standard immunoblotting assays, as previously described 21 using the following antibodies: anti-phospho-JNK (sc-6254), anti-JNK1 (sc-474), anti-phosphoMKK4 (sc-7990), anti-MKK4 (sc-964), all purchased from Santa Cruz Biotechnology, Heidelberg, Germany, b-tubulin (05-661), anti-MnSOD (06-984) from Upstate Biotechnology, Lake Placid, NY, USA, catalase (219010), GSTP1-1 (354212) and glutathione peroxidase (ST1000) from Calbiochem, La Jolla, CA, USA. The intensity of the protein bands was quantified by densitometric analysis on scanned films with the 'Scion Image Software' (Scion Corporation, Frederick, MD, USA). Densitometric values of phospho-JNK protein levels for each time point of drug exposure were referenced to the 'no drug' value corresponding to cells cultured in the absence of any drug, JNK activator, upregulation of basal phospho-JNK levels X2-fold in patient bone marrow mononuclear cells occurring at any time point during an 1 h in vitro treatment with 1 mM daunorubicin. The upregulation of phospho-JNK levels was determined by western blot analysis in comparison to the 'no drug' values as described in 'Materials and methods'.
after normalization against the level of the b-tubulin expression in the same sample. A clear upregulation of phospho-JNK levels X2-fold compared to the 'no drug' value occurring at any time point during the 1 h drug treatment was considered significant.
Assessment of apoptosis and intracellular anthracycline accumulation by flow cytometry
To determine the extent of drug-induced apoptosis, DNR or DOX-treated leukemia cells were stained with fluoresceinisothiocyanate (FITC)-conjucated annexin-V and propidium iodide using the annexin-V-FITC kit (BD Biosciences, Pharmingen, San Diego, CA, USA) according to the manufacturer's protocol. The intracellular accumulation of anthracyclines on the basis of their fluorescence properties has been described previously. 22 The cellular incorporation of DNR or DOX in anthracyclinetreated cells was determined as the ratio of the mean cellular fluorescence intensity (MFI) on the single parameter red fluorescence histogram for each sample divided by the MFI of untreated control cells. At least 10 000 cells per sample were analyzed (EPICS XL, Coulter, Fullerton, CA, USA). Cells cultured in the absence of the drugs served as controls in all cases. In each experimental condition, three independent experiments in triplicate were performed.
Transient transfection experiments
U937R cells were transiently transfected either with pEBG SEKED (SEKED is a constitutively active mutant form of SEK1/ MKK4) or empty vector pEBG. 23 Plasmids were a kind gift of Dr John Kyriakis, Tufts University School of Medicine. Transfection was performed by electroporation (242 V, 975 mF) in serum-free medium (Optimem; Invitrogen). Transfection efficiency (approximately 40%) was evaluated by co-transfecting cells with the vector pGFP-N1 (Clontech, Saint-Germain-en Laye, France).
RNA interference knockdown of JNK
The 'BLOCK-iT Pol II miR-MAPK8 Validated miRNA Vector DuoPak' (Invitrogen), which is based on the miRNA vector system and includes endogenous murine miR-155 flanking sequences and a spectinomycin resistance gene was used for knockdown of JNK1. Transfection of U937 cells (10 8 cells per ml), was carried out with electroporation (242 V, 975 mF) using 20 mg of purified pcDNA6.2-GW/EmGFP-miR-MAPK8 Validated miRNA Vector (JNK1-miRNA) or a vector containing a negativecontrol mismatch sequence (empty vector). Stable transfectants were selected in medium containing 6 mg/ml blasticydin for 2 weeks. Knockdown of JNK1 was confirmed by western blot.
Assessment of P-gP protein expression and P-gP efflux by flow cytometry
The P-gP protein expression was determined by labelling leukemic cells with a PE-conjugated mouse monoclonal antibody directed against the extracellular conformational epitope of P-gP (UIC2 clone, Chemicon, Millipore, Temecula, CA, USA), as previously described. 24 Appropriate isotypic controls were used. For measurement of the function of P-gP we performed the calcein AM assay as previously described. 25 The relative activity of P-gP is calculated as the ratio of the MFI of calcein AM in the presence of the P-gP modulator CsA divided by the MFI of calcein AM without modulator after subtraction of the fluorescence of the control unloaded cells. 
Assessment of reactive oxygen species
Statistical analysis
Clinical and biological factors were investigated for their relevance by the Fisher exact test for binary variables and by the Student's t-test or Mann-Whitney U-test for continuous variables. Po0.05 was considered significant.
Results
Anthracycline resistance of U937R cells is not exclusively attributed to P-gP activity
Anthracycline compounds are widely used to treat leukemias. 1 Resistance to anthracyclines in AML has been mainly attributed to P-gP, a 170-kDa glycoprotein expressed at the cell surface that inhibits the drug to reach its target by effluxing it out of the cell. We analyzed mechanisms of apoptosis resistance in U937R AML cells which were selected after exposure of U937 cells to increased concentrations of anthracyclines. 19 In vitro treatment of the parental U937 cells with DNR induced a dose-and timedependent apoptosis, and 12 h of exposure to 1 mM DNR resulted in annexin-V positivity in nearly 50% of the cells (Figure 1a ). In contrast, U937R cells showed remarkable resistance to anthracycline as 10 mM DNR treatment up to 72 h could not induce any apoptosis ( Figure 1a) . We analyzed the P-gP expression by flow cytometry in U937 and U937R cells and the P-gP efflux pump activity by a calcein AM-based functional assay. As U937R cells revealed a 6.6-fold expression of P-gP and a 20-fold efflux pump activity, as compared to the low levels of P-gP expression and activity in U937 cells, one can hypothesize that apoptosis resistance in U937R cells was due to increased drug efflux (Figure 1b) . Indeed, exposure of P-gP( þ )ve U937R cells to low doses of DNR (1 mM) or DOX (1.5 mM) revealed a reduced intracellular drug accumulation in contrast to the anthracycline-sensitive P-gP(À)ve U937 cells (Figure 1c i-vi and results not shown). However, at higher doses of anthracycline treatment (5-10 mM DNR) the P-gP activity in the U937R was overwhelmed as 490% of the cells showed DNR incorporation with kinetics similar to sensitive U937 cells ( Figure 1c vii-ix). Given that DNR( þ ) U937R cells were nonapoptotic ( Figure 1c viii-ix), we conclude that besides P-gP activity, other mechanisms are also implicated in the defective apoptosis observed in U937R cells.
JNK1 activity is strongly induced by anthracyclines in sensitive U937, but not in anthracycline-resistant U937R and URD40 AML cells JNK activation has been proposed to mediate apoptosis in chemotherapy-treated leukemia cells. 8 The fact that reduced drug incorporation could not exclusively explain the apoptosis resistance of U937R prompted us to investigate the activation potential of JNK in these cells. To this aim U937 and U937R cells were exposed to DNR and DOX and the levels of activated phospho-JNK in anthracycline-treated cells were analyzed by western blot at various time points. Treatment of the drugsensitive U937 cells with low doses of anthracyclines (1 mM DNR or 1.5 mM DOX) resulted in a rapid, within 15 min, activation of JNK (Figure 2 and not shown). On the contrary, these DNR and DOX concentrations failed to activate JNK in U937R cells at the same time frame and at longer incubation periods, up to 6 h ( Figure 2 and results not shown). Furthermore, treatment of U937R cells with higher doses of DOX and DNR up to 10 mM did not activate JNK in these cells (Figure 2 ). We also evaluated another anthracycline-resistant AML cell line, URD40 cells, for their JNK activation potential and we found that JNK was not activated in URD40 cells exposed to anthracyclines either ( Figure 2 ). These findings were despite of our observation that U937R and URD40 cells exhibited normal JNK protein levels ( Figure 2 ). Taking together, these data suggest that anthracycline-resistant AML cell lines exhibit a JNK activation failure when exposed to anthracyclines. As chemotherapy-induced JNK activation is suggested to promote apoptosis, deregulation of the JNK pathway may represent an alternative mechanism of apoptosis resistance in anthracyclineresistant AML cells.
Downmodulation of JNK in sensitive U937 cells makes them resistant to anthracyclines
To further investigate the significance of drug-induced JNK activation, we examined if down-regulation of the JNK pathway in sensitive U937 cells could induce an anthracycline resistance. U937 cells were stably transfected with two distinct validated miRNA-expression vectors, which target JNK1 (JNK1/ miRNA A and B) or with a vector containing a negative-control mismatch sequence (empty vector). The expression levels of JNK1 were downregulated in U937 transfected with JNK1/ miRNA A and B compared to empty vector cells or untransfected U937 cells (Figure 3a ). Apoptosis after 24 h of treatment with DNR (1 mM) and DOX (1.5 mM) was reduced by a mean of 50.4 and 61.3%, respectively, in U937 cells transfected with JNK1-miRNA A as compared to empty vector or untransfected U937 cells (Po0.001; Figure 3b ). Similar results were obtained by silencing the expression of JNK using the JNK1/miRNA B validated vector (Po0.001; Figure 3b ). Consistent with these results, pretreatment of these cells with the cell-permeable JNK inhibitor 420116 (1 mM; Calbiochem) decreased to a less but yet significant extent DNR-induced apoptosis (1 mM DNR, 24 h) compared to cells treated with a negative control peptide (mean±s.d. ¼ 59.3±2.6 vs 71.6±4.2, P ¼ 0.013o0.05).
Activation of JNK in the resistant U937R cells sensitizes them to anthracyclines
To determine if the absence of anthracycline-induced JNK activation in U937R associates with the apoptosis resistance observed in these cells, we investigated whether selective restoration of the inactive JNK-signaling pathway in U937R cells could increase their chemosensitivity. For this, we transiently transfected U937R cells with a constitutively active form of SEK1/MKK4 (SEKED), an upstream activator of JNK or with the empty vector. Transfection efficiency was 39±5% (n ¼ 3) and SEKED transfectants expressed higher levels of phospho-MKK4/ SEK1 and higher basal and drug-stimulated levels of phospho-JNK, compared to control cells (Figure 4a ). We subsequently incubated SEKED and empty vector U937R with and without 1 mM DNR or 1. U937R + DNR 5µM Figure 2 Daunorubicin (DNR) treatment upregulates phospho-JNK (c-Jun N-terminal kinase) protein levels in sensitive U937 cells but not in resistant U937R and URD40 cells. U937, U937R and URD40 acute myeloid leukemia (AML) cells were cultured in the absence (no drug) or in the presence of various concentrations of DNR for indicated time periods and phospho-JNK and total JNK1 protein levels were determined by western blot analysis of total cell lysates using specific antibodies. U937*; cell lysates from U937 cells exposed to 1 mM DNR for 60 min.
In conclusion, our data from the in vitro cell line system indicate a central role of the JNK pathway in mediating apoptotic cell death after anthracycline treatment in AML cells. More important, intrinsic failure of JNK activation or blockage of JNK activation is related to anthracycline resistance. We therefore evaluated patterns of JNK activation in primary AML cells from patients treated with anthracycline-containing chemotherapy and correlated the results with chemotherapy outcome.
Absence of JNK activation in primary AML blasts exposed to anthracyclines associates with a poor response of AML patients to standard induction chemotherapy
We analyzed the JNK pathway in 29 bone marrow samples obtained from patients with AML (Table 1) . A total of 10 AML patients achieved complete remission after one course of anthracycline-containing chemotherapy and 8 patients showed refractory disease, whereas the remaining 11 patients were not evaluable for response to chemotherapy due to early death (n ¼ 2) or palliative care only therapy (n ¼ 9). Considering our in vitro results that failure of activation of the JNK pathway relates to anthracycline resistance, we assessed the inducibility of phospho-JNK in AML primary cells after short term (30-60 min) in vitro exposure to DNR (1 mM) and correlated it with clinical data. Unstimulated phospho-JNK levels in primary cells cultured in the absence of DNR (no drug) did not significantly correlate with treatment outcome. In 10 out of the 29 primary AML samples (34.5%) the in vitro treatment with DNR resulted in a X2-fold increase of phospho-JNK as compared to the unstimulated levels of phospho-JNK (mean fold increase ¼ 14, range 2-89, JNK activators), whereas the remaining 19 (65.5%) samples did not reveal any significant increase in JNK activity (mean fold change of baseline levels ¼ 1, range 0.3-1.5, JNK nonactivators; Figure 5a ). Interestingly, all eight patients that exhibited primary resistance to chemotherapy belonged to the group that failed to upregulate phospho-JNK in vitro (JNK nonactivators). On the other side, the 6 out of the 10 chemoresponders belonged to the JNK activators group (P ¼ 0.012 o0.05). In another way of analysis, AML primary samples from chemoresponders exhibited significantly higher fold upregulation of phospho-JNK after in vitro DNR treatment as compared to AML cells from chemorefractory patients (mean ± s.e.m.; 11 ± 8 vs 1 ± 0.1, P ¼ 0.02; Figure 5b ). In addition, the absence of drug-induced JNK activation correlated with other bad characteristics of AML, like AML evolving from antecedent myelodysplastic syndrome (MDS; P ¼ 0.017) and patient age (median age of non-JNK activators 75 vs 64.5 years, P ¼ 0.046). Statistical associations between the JNK activation patterns after in vitro exposure of primary AML blasts to DNR with patient clinical parameters are summarized in Table 2 . As these bad AML characteristics (age, MDS-related AML and chemoresistance) have been also associated with increased P-gP efflux pump activity we investigated among the eight chemoresistant AML patients belonging in the non-JNK activation group their functional status of P-gP. We found an important modulatory effect of the P-gP inhibitor cyclosporine A on calcein AM uptake only in two chemoresistant non-JNK activators underscoring the main role of JNK activation pattern in chemoresistance (data not shown). Altogether, our in vivo results suggest that a defective phospho-JNK response to chemotherapy may characterize AML cases with inferior responsiveness to treatment and distinct biologic and clinical attributes.
JNK activation failure of U937R cells is not a downstream consequence of a defect of U937R to generate ROS
As reactive oxygen species (ROS) are recognized in anthracycline-treated cells as key upstream messengers of the JNK pathway, 14 we investigated if changes in the oxidative status of chemoresistant AML cells might underlie the observed suppression of the JNK pathway in these cells. To this end, the differential ability of sensitive U937 and resistant U937R AML cells to generate ROS was evaluated. Intrinsic ROS levels were 2.1-fold higher in resistant U937R cells as compared to parentalsensitive U937 cells (mean±s.d.: 211.3±34 vs 97.48±8.72, Po0.001). However, treatment with anthracyclines (1 mM DNR, 5-60 min) upregulated intracellular ROS to the same extent both in sensitive and resistant AML cells (Supplementary Figure 2A) . Also, sensitive U937 and resistant U937R cells exhibited similar expression levels of the antioxidant enzymes catalase, MnSOD, GPx and GSTP1-1 (Supplementary Figure 2B) . These results suggest that the suppression of the JNK pathway in anthracycline-resistant U937R AML cells is not a downstream consequence of a defect of U937R cells to generate ROS.
Discussion
JNK activation is a dynamic signaling response to cellular stress, including irradiation and cancer chemotherapeutics. [7] [8] [9] Fibroblasts from JNK knockout mice were remarkably resistant to apoptosis induced by several stressful stimuli, suggesting that JNK is essential for stress-induced apoptosis. 26 We found, in accordance with the data previously published by Mansat-de Mas et al. 13 that the anthracyclines DNR and DOX rapidly activated JNK in drug-sensitive U937 AML cells, indicating that anthracycline-induced apoptosis in leukemia cells is also mediated by JNK activation. Although these observations suggest that JNK activation may be a proapoptotic response of drug-sensitive AML cells to standard chemotherapy, it is not known if chemoresistance in AML may be attributed to failure of the cells to activate JNK. In the present report we show that in the anthracycline-resistant AML the JNK-signaling pathway is not functional and this defect may be the cause of the resistance. Our in vitro findings in anthracycline-resistant leukemic cell lines and most importantly, our data from primary leukemic cells obtained from AML patients being in vivo refractory to standard induction chemotherapy, support this conclusion.
First, we observed a failure of anthracyclines to activate JNK in drug-resistant U937R and URD40 AML cells whereas drugsensitive U937 cells exhibited robust JNK activation. JNK activation was not seen also after long incubation periods excluding the possibility that there is no real failure but only late response. Our findings are in line with previous reports in solid cancer cell lines which showed defective JNK response to chemotherapy in P-gP( þ ) multidrug-resistant mouse mammary carcinoma cells and in DOX-resistant breast cancer cells. 16, 17 However, in these studies one can not exclude that these results arise from insufficient intracellular drug to trigger JNK activation due to drug efflux by P-gP. We show here that the inability of the U937R AML cells to activate JNK was seen though the drug was accumulated intracellularly, indicating that the JNK-activation failure of anthracycline-resistant AML cells is an intrinsic characteristic of these cells. Second, we found that downregulation of JNK1 by RNA interfering remarkably protected drug-sensitive U937 cells from DNR and DOX-induced apoptosis. In another experimental approach, we also found that pretreatment of U937 cells with the known cell-permeable JNK inhibitor 420116, which inhibits JNK phosphorylation and subsequent activation, makes them resistant to DNR (data not shown). These findings confirm the data previously published by Mansat-de Mas et al. 13 who suggested a temporal association between DNR treatment, JNK activation and apoptosis in U937 cells and additionally show that (1) JNK is a direct mediator of apoptosis in anthracyclinetreated AML cells and (2) the blockage of JNK activation induces anthracycline resistance. JNK activation may mediate apoptosis by phosphorylating members of the AP-1 transcription factor complex, mainly c-Jun. 9 Alternatively, JNK activation may initiate the release of cytochrome c and thus the mitochondrial apoptotic pathway. 26 Although we did not analyze the downstream targets of JNK activation in anthracycline-treated AML cells, it is likely that the main mechanism by which JNK suppression induces anthracycline resistance is through directly blocking apoptosis. However, Zhou et al. showed that adenovirus-mediated upregulation of the low p-JNK level found in PgP( þ ) solid tumor cells increased anthracycline incorporation in these cells and reversed P-gP-related resistance, suggesting that JNK may also downregulate P-gP. 27 Although other reports in solid tumors argue against such an association, 28 the study by Zhou et al. indicates that in some experimental systems JNK suppression may additionally induce resistance through favoring a P-gP( þ ) phenotype.
Third, in order to show that antracycline resistance and JNKsignaling pathway are directly linked, we selectively activated the impaired JNK pathway in the resistant U937R cells. We found that restoration of JNK pathway in U937R cells reversed their resistance to anthracyclines and made them susceptible to drug-induced apoptosis. In accordance to that, recent studies showed that molecular-targeted therapies which effectively induced apoptosis in previously resistant AML cells, did so by ultimately succeeding to activate JNK. [29] [30] [31] Davison et al. also suggested that activation of the JNK pathway correlates with reversal of drug resistance by showing a temporal association of L-buthionine-[S,R]-sulfoximine treatment, JNK activation and sensitization of arsenic trioxide-resistant NB4 acute promyelocytic leukemia sublines to arsenic. 32 We evaluated our in vitro results in bone marrow cells obtained from AML patients before chemotherapy and confirmed the hypothesis that chemoresistance may be attributed to failure of JNK activation. We monitored the dynamic changes of phospho-JNK levels of primary leukemic cells after their in vitro exposure to anthracyclines. We found that all of our patients that were refractory to one induction chemotherapy failed to activate JNK. In contrast, most of the patients responding to induction chemotherapy rapidly triggered JNK activation in their leukemic cells. Although our sample is small, the clear segregation of the two subgroups together with our in vitro data suggests that the association between JNK failure and chemoresistance found here are etiologically linked. In line with that, Sampath et al. 33 analyzed AML blasts obtained from patients 1 day after treatment with cytarabine and an investigational kinase-inhibitor UCN-01 and found a correlation between JNK activation and response to treatment. In addition, this study suggests that the probable role of JNK activation as an indicator of response to AML induction chemotherapy is probably not restricted to anthracyclines. Nevertheless, JNK activation ability may be used as a pharmacodynamic assay to guide treatment decisions, especially in the elderly in which the question to give or not to give chemotherapy remains a major challenge. The detection of upregulation of phospho-JNK in primary blasts may favor the administration of anthracycline-containing standard chemotherapy whereas AML patients who do not activate JNK should be given alternative treatments. Flow cytometry requires less primary material and may also be utilized, besides western blot, for detection of phospho-JNK levels in such a clinical screening. We found that anthracycline resistance in AML cells may be reversed by selective stimulation of the JNK-signaling pathway. Treatment with escalated concentrations of anthracyclines do not restore JNK activation neither in resistant AML cell lines nor in primary AML samples suggesting that JNK-related drug resistance is unlikely to be circumvented through anthracycline dose escalation (Figure 2 and not shown). Therefore, a significant question is how the JNK-signaling response to anthracyclines is abrogated and how this knowledge can be used therapeutically? One possibility might be that the JNK1 gene in chemoresistant AML cells is not functional. However, this is unlikely, as this gene is functionally redundant and the resistant AML cell lines and all AML patient samples examined strongly expressed JNK1 protein. Alternatively, JNK phosphorylation in resistant AML blasts may be directly inhibited at the protein level through protein-protein interactions. Glutathione S-transferase P1-1 (GSTP1-1) is an antioxidant enzyme also shown to inhibit JNK signaling through direct interaction with JNK C terminus. 34 Although GSTP1-1 was strongly expressed in primary cells from all chemoresistant non-JNK activator AML patients examined, we did not detect a GSTP1-1/JNK heterocomplex by immunoprecipitation analysis (data not shown). However, it is possible that the primary lesion does not directly involve JNK but rests in mediators of the JNK pathway upstream or downstream to JNK. As ROS are essential upstream activators of JNK in anthracycline-treated cells, 14 we investigated if JNK suppression in the chemoresistant AML cells mechanistically relates to a defect of resistant cells to generate ROS. Our data argue against this possibility, as we detected similar ROSgenerating ability and expression of antioxidant enzymes in the anthracycline-sensitive and resistant AML cell lines. Aberrant expression/function of the large number of MAP3K kinases upstream to JNK (MEKK's, MLK's, DLK, ASK1/2, TAK1 and TPL2), 7 or of the downstream-negative regulators of JNK signaling (for example, MAPK-phosphatase family proteins) in resistant AML cells, 35 may also represent other mechanisms of JNK suppression in resistant AML blasts. However, it is also possible that the suppression of anthracycline-induced JNK signaling is more complex. Upregulation of pathways such as PI3K/Akt, MEK/ERK, heat-shock proteins (Hsp's) and nuclear factor-kB have also been implicated in the interruption of JNK activation. 30, 36, 37 In fact, molecular therapies targeting pathways other than the JNK pathway have been shown to lead to restoration of JNK and reversal of resistance. [29] [30] [31] 38, 39 In conclusion, our findings indicate that JNK activation after conventional anthracycline-containing chemotherapy for AML is a proapoptotic response, which when abrogated, contributes to drug resistance. We also suggest that surrogate in vitro assays evaluating the pattern of change of phospho-JNK levels in chemotherapy-treated AML cells may represent a 'dynamic' approach yielding valuable information to guide treatment decisions in AML. These findings may also provide the basis to explore JNK targeting as a new therapeutic approach in AML. However, in the effort to therapeutically target JNK it should be taken under consideration that drug resistance in AML is not univocal but probably results from a complex network of events concurrently affecting distinct cellular processes: drug-target interactions, DNA repair and drug-triggered-signaling pathways/ apoptosis. Future research is needed to shed light on how these distinct resistance mechanisms, including JNK refractoriness, functionally cooperate in a drug-resistant AML cell (possible interactions, the interval of drug concentrations within which each mechanism is critical for drug resistance, their respective function in normal cells). In this vein, understanding the specific aberrations underlying the suppression of anthracyclineinduced JNK activation in a cohort of chemoresistant AML may enable the identification of combined-targeted therapies to counteract resistance to anthracyclines in this subgroup of patients. PEBG-SEKED construct. We thank Prof Panagiota Matsouka (Patras University) for critical discussions. We thank Lorna Pherson for excellent laboratory assistance, Maria Themeli for critical discussions and Aristotelis Klamargias for help in statistical analysis. Table 2 JNK activation patterns after in vitro exposure of primary AML blasts to daunorubicin and patient age or disease biology or response to induction chemotherapy Failure of JNK activation in chemoresistant AML ED Lagadinou et al
